Learn more about the LymeX Diagnostics Prize on July 13, 2022 at the technical considerations webinar. Dr. John Aucott and Dr. Liz Horn will introduce scientific and technical principles to support entrants with their submissions. The session will cover the fundamentals of Lyme disease detection and considerations for development and evaluation of diagnostics.
A video recording and summary of questions and answers will be published following the session. Watch the recording of the June 16 virtual information session.
Phase 1 of the LymeX Diagnostics Prize calls on scientific, technical, and clinical experts to submit innovative methods for detecting active Lyme disease infections in people. The ultimate goal of the competition is to advance the development of these diagnostics toward Food and Drug Administration (FDA) review.
The competition seeks concept papers that describe proposed solutions and scientifically rigorous rationales for success, including ambitious but achievable roadmaps for prototyping, iteration, testing and validation, and evaluation. Entrants should also indicate their anticipated pathway toward eventual FDA review and clearance.
Up to 10 Phase 1 winners will receive an equal share of the $1 million Phase 1 prize pool. If the planned Phase 2 moves forward, the winners of Phase 1 will be invited to participate in the second phase (Phase 2) of the competition.
Explore fundamentals about Lyme disease, details on the LymeX Innovation Accelerator (LymeX) partnership, tools for patient-centered design, regulatory and commercialization considerations, and more in the competition resources.
Transforming diagnostics for Lyme disease will only be possible through collaborative innovation among patients, advocates, academia, nonprofits, industry, and government. Register for the competition entrant community to identify opportunities to collaborate with others or add members to your team.
To receive all competition updates, subscribe to the LymeX Diagnostics Prize newsletter and follow @Lyme_X on Twitter.